EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Evaluating high-cost technologies – no need to throw the baby out with the bathwater

Gurdeep S Sagoo, Tomos Robinson, Diarmuid Coughlan, Nick Meader, Stephen Rice, Luke Vale

Expert Review of Pharmacoeconomics & Outcomes Research · 2023

DOI: 10.1080/14737167.2023.2263647 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2023. Verfasst von Gurdeep S Sagoo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, UK. Hauptthemen laut MEDLINE: Technology, High-Cost, Technology Assessment, Biomedical. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Evidence generation for the health technology assessment (HTA) of a new technology is a long and expensive process with no guarantees that the health technology will be adopted and implemented into a health-care system. This would suggest that there is a greater risk of failure for a company developing a high-cost technology and therefore incentives (such as increasing the funding available for research or additional market exclusivity) may be needed to encourage development of such technologies as has been seen with many high-cost orphan drugs. AREAS COVERED: This paper discusses some of the key issues relating to the evaluation of high-cost technologies through the use of existing HTA processes and what the challenges will be going forward. EXPERT OPINION: We propose that while the current HTA process is robust, its evolution into accommodating the incorporation of real-world data and evidence alongside a life-cycle HTA approach should better enable developers to produce the evidence required on effectiveness and cost-effectiveness. This should lead to reduced decision uncertainty for HTA agencies to make adoption decisions in a more timely and efficient manner. Furthermore, budget impact analysis remains important in understanding the actual financial impact on health-care systems and budgets outside of the cost-effectiveness framework used to aid decision-making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Technology, High-CostTechnology Assessment, BiomedicalHumansUncertaintyBiomedical TechnologyOrphan Drug ProductionCost-Benefit Analysis

Stichwörter der Autor:innen

High-cost technologiesevidence generationhealth technology assessmentlife-cycle health technology assessmentreal-world data

Autor:innen und Institutionen

  • Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, UK.

Zitieren

APA

Sagoo, G. S., Robinson, T., Coughlan, D., Meader, N., Rice, S., & Vale, L. (2023). Evaluating high-cost technologies – no need to throw the baby out with the bathwater. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2023.2263647

Vancouver

Sagoo GS, Robinson T, Coughlan D, Meader N, Rice S, Vale L. Evaluating high-cost technologies – no need to throw the baby out with the bathwater. Expert Review of Pharmacoeconomics & Outcomes Research. 2023. doi:10.1080/14737167.2023.2263647

BibTeX
@article{Sagoo2023,
  author = {Sagoo, Gurdeep S and Robinson, Tomos and Coughlan, Diarmuid and Meader, Nick and Rice, Stephen and Vale, Luke},
  title = {Evaluating high-cost technologies – no need to throw the baby out with the bathwater},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2023},
  doi = {10.1080/14737167.2023.2263647}
}
Kostenlos starten →